CABG - update. Sahar Gideon MD

Transcription

1 CABG - update Sahar Gideon MD מ נהל המ חלקה לני ת ו ח י לב המרכז הרפואי סורוק ה השתלמו ת לבוגרי התמ ח ו ת בקרדיו לוגיה 2010

2 Percutaneous Coronary Interventions 1977: 1 st Coronary angioplasty by Gruntzig Limitation: restenosis (PCI)

3 Open Heart Surgery - Israel year Total CABG

4

5 META-ANALYSIS ANALYSIS of 13 RCT CABG vs PCI Hoffman SN et al: JACC 2003 opatients: 2/3 had 2VD (41% prox LAD disease) and 100% had normal LV function Excluded patients (L L main, severe/complex 3VD, occlusions, poor LV) 5 yr RESULTS All trials PCI vs CABG FREEDOM FROM nos % RD (95% CI) favouring CABG ALL DEATH ( ) Cardiac Death ( ) REINTERVENTION (31-44) < Repeat CABG (16-27) < Repeat PCI (16-30) < Death/MI MI/Revasc (21-41) < Angina ( ) A small survival advantage (p=0.02, NNT=53) A marked reduction in the need for reintervention (p<0.001, NNT=4) p NNT

6 Adjusted Survival Curves : 2CAD without LAD 2CAD +Prox LAD 3CAD +Prox LAD

7 CABG is associated with lower rates of death or MI and repeat revascularization for 2 and 3 vessel disease Multivessel disease DES(N = 9963) CABG(N = 7437) in New York State

8 6033 pt s s treated with DES 13,738 pt s s treated with BMS DES were associated with increased rate of death, as compared with BMS after six months N Engl J Med 2007;356:

9 Circulation, Mar 2005; 111:

10

11 Appropriate : Score 7 to 9 Uncertain : Score 4 to 6 Inappropriate: Score 1 to 3

12 Medical treatment

13 Probability of survival free of overall mortality 611 pt s CABG 203 PCI 205 MT 203 (P = 0.631) Survival (P =0.0026) Conclusions : Long-term events and rate of additional revascularization MT similar to PCI. Event free CABG was superior to MT in terms of the primary end points, reaching a significant 44% reduction The primary end points were total mortality, Q-wave myocardial infarction, or refractory angina requiring revascularization. Circulation. 2007;115:

14 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Randomized trial 2287 pt s F/U median- 4.6yr

15 3,675 - PCI 3,838 medical J Am Coll Cardiol 2008;52:

16 Diabetes Mellitus

17

18 SIRIUS Reduced Efficacy in IDDM In-Segment Restenosis P<0.001 P=NS 50.7% 50.0% % P< % 35.0% 6.1% 12.3% Non-diabetic DM-Oral Agent DM- Insulin Sirolimus Control

19

20

21 Pedicled IMA harvesting was related to a higher incidence of sternal complications, both in the LIMA and in the BIMA group Ann Thorac Surg 2005;80:888 95

22

23 LV Dysfunction

24 3,088 pt s 80% reduction in mortality for pt s with viability treated by revascularization When 25% to 30% of the LV is viable by noninvasive testing, revascularization might be considered

25 יש ל י תו ר לנ יתו ח י "ח זה"...

26 Prospective randomized trial 282 pt s ;mean age- 80 yr 14 centers in Switzerland Time to Death or Nonfatal MI Rates of Major Adverse Clinical Events (MACE) INV - symptom relief cost intervention MT - 50%late nonfatal events

27 Left Main Disease

28 Left main stenosis PCI vs. CAVG LM is a potentially attractive target for PCI because of its large diameter and proximal position Two important pathophysiological features may mitigate against the success of PCI: (i) bifurcation Up to 80% of LM disease involves the bifurcation known to be at particularly high risk of restenosis multivessel (ii) Up to 80% of LM patients also have multivessel CAD where CABG, as already discussed, may already offer a survival advantage.

29

30 Drug eluting stents (DES) vs BMS in Left Main Chieffo/Colombo Circ BMS 85DES Valgimigli/Serruys Circ BMS 95 DES 30 day % Mortality 7 11 % Repeat Revascularization 2 0 % MACE months % Mortality 9 4 % Repeat Revascularization % MACE months % Mortality % Repeat Revascularization 23 6 % MACE 45 24

31

32

33 10.3 Early post-operative operative risk The survival outcome for all CABG operations performed in the UK in the period showed : 1.1% hospital mortality in 78,367 elective patients. 2.6% in 32,990 urgent patients. In all pt s s without and 30,218 pt s s with LM stenosis,, the respective mortalities were 1.5% and 2.5% (respective predicted elective mortalities 0.9% and 1.5%). In all pt s s without or 26, 020 pt s s with DM, the respective mortalities were 1.6% and 2.6% (respective predicted elective mortalities 1.0% and 1.6%).

34

35 Do you prefer a reintervention or a CVA?

36

37 STS

38

39

40

41 RESULTS OF AORTIC NO-TOUCH MYOCARDIAL REVASCULARISATION: A COMPARATIVE ANALYSIS IN 1713 PATIENTS M. Albert, Germany Group A :Complete no aortic touch technique - OFFPUMP (n=679) Group B :ON/OPCAB + partial clamping of the aorta (n=1034) RESULTS : Group A Group B P Mortality (30d) 4 (0.6%) 24(2.3%) <0.05 CVA 1(0.1%) 7(0.7%) <0.05 Conclusions Total arterial revascularisation with bilateral ITA graft using the aortic no touch technique allow the reduction of cerebrovascular event after CABG to zero

42

43

44

45

46

47

48

49

50

51

52 1005 pt s

53

54 Eur. Heart J. October 2, 2010

55 Heart Team Heart Team - cardiac surgeon, and an interventional cardiologist. Myocardial revascularization should in general not be performed at the time of diagnostic angiography, thereby allowing the Heart Team sufficient time to assess all available information, reach a consensus, and clearly explain and discuss the findings with the patient.

56 6.7 Recommendations

57

58

59 CABG CABG DEALS WITH THE CULPRIT LESION AND ANY FUTURE CULPRIT LESION (because graft is to mid vessel) BUT PCI only deals with suitable culprit lesion CABG COMPLETE revascularization

60

61

62

63 Controversial Definition 1: Traditional revascularization was defined as all diseased arterial systems receiving at least one graft insertion. Definition 2: Functional revascularization was defined as bypassing all diseased primary coronary segments (LAD,LCX,RCA) Nondiseased vessel : <1.5 mm in diameter regardless of the degree of stenosis, or with a stenosis of <50%.

64 1034pt s

65 Arterial Re vascularization

66 Effect of LIMA SVG compared to LIMA to LAD: X 1.61 risk of death in 10 y X 1.41 risk of late MI X 2.00 risk of re-operation Loop et al, N Engl J Medicine 1986

67 LIMA + RIMA Resistance to atherosclerosis. Production of vasodilators nitric oxide and prostacyclin - "downstream" effect Response to : vasodilators (milrinone( + nitroglycerin) No Response to Norepinephrine. Remodeling - adapting to demand

68 Effect of Bilateral IMA 10 y outcomes: 76% survival compared with 85% with bilateral IMA Pick et al Ann Thoracic Surg y outcomes: Bilat IMA had improved survival and reduced re-interventions Lytle et al, Ann Thorac Surg 2004

69 Comparison of the bilateral ITA (BITA) and single ITA (SITA) groups in terms of survival (A) and reoperationfreesurvival (B).

70 Single (SIMA) IMA grafts were used in 490 Multiple (MIMA) IMA grafts in 377,, along with concomitant saphenous veins. BIMA BIMA BIMA 59% BIMA

71 One year gained

72 Pedicled Skeletonized

73 Flow of ITA harvested as pedicled or skeletonized conduit.

74 pain Lt skeletonized and a Rt nonskeletonized Circulation. 2006;114:

75 T garft

76 40 pt s 6 months - angiography

77 Radial artery : 5-year patency : 83-95% Very susceptible to competitive flow. The graft failure rate is higher if : 1. The target vessel stenosis is less than severe 2. On the right coronary system.

78 231 radial artery anastomoses Angiography -109 patients Mean 27.1 mo postop for symptoms of ischemia. Cumulative patency for RA anastomotic locations. Cumulative RA patency associated withproximal target stenosis: P <.001). The relative risks for the targets of the RCA were statistically significant versus those of the LAD (P =.01) and bordered on significance versusthose of the circumflex artery J Thorac Cardiovasc Surg 2002;123:45-52

79

80 Gstroepiploic J Thorac Cardiovasc Surg 120: ;2000 Ann Thorac Surg 2004;78:2033 6

81 Radial LIMA RIMA At 10 ; 15 yrs LITA - 95 and 88% SVG - 61 and 32% SVG

82

83 Coronary Artery Reoperations 21,568 pt s who underwent bypass surgery from showed a steady decrease in the number of patients undergoing redo coronary artery operations.

84 RESULTS OF CORONARY ARTERY REOPERATIONS STS database - in-hospital mortality rate of 6.95% ( ). 1993). Recent mortality rates from other large series range from 4.2 to 11.4%, most being around 7% times higher than the risk of primary CABG.

85 CORONARY ARTERY REOPERATIONS Axial CT image : Preoperative assessment for aortic valve replacement in a 67-year-old man who had undergone CABG.

86

87 Factors favoring PTCA Early (<5 years) stenoses Single stenotic vein graft Focal graft lesions Patent ITA-LAD graft Normal left ventricular function

88 9.6 Crossed revascularization procedures

89 Off Pump Coronary Bypass

90 C.P.B חס רו נ ות פגי ע ה במ ער כ ת קרי ש ת הדם ש פ ע ול ה מנגנון הדל ק ת י בגוף response ריאות הרקמ ת יי- בזי לו ח הפרעה נזקי ם נוירולוג ים הפרע ו ת קוגניטיב יו ת inflamatory כליו ת,

91 Off PUMP Revascularization without the potential complications of extracorporeal support % of all procedures performed in the United States. Completeness of Revascularization and Graft Patency? Technically demanding Learning curve

92 Off Pump Coronary Bypass Only 1 randomized study 200 patients: Similar graft patency,, similar cardiac outcomes, lower cost.. Puskas et al, JAMA 2004 Off-pump coronary artery bypass surgery may be superior to conventional CABG in many patients, especially those who are considered high-risk 1 Reduced transfusions and bleeding 2,4 Reduced inotropes 2,4 Reduced arrhythmias 2-4 Reduced sternal wound infection 2-4 Reduced cerebral emboli and cognitive dysfunction 3 Reduced postoperative hospital length of stay 2

93 12,812 consecutive pt s Ten-year survival data Four groups: OPCABG 1-3 grafts (n = 3,946) OPCABG 4-7 grafts (n = 1,721) On-pump CABG 1-3 grafts (n = 3,380) On-pump CABG 4-7 grafts (n = 3,765) ICOR - Index of Completeness of Revascularization

94 Patients Most Likely to Benefit from OPCAB Atheromatous calcified aorta Patients with significant comorbidities: Cerebral vascular disease Peripheral vascular disease Hepatic disease Bleeding disorders COPD Renal dysfunction Reoperative surgery Patients who refuse blood products

95 Minimally Invasive Myocardial MINIMALLYINVASIVEDIRECT CORONARY ARTERY BYPASS (MIDCAB) Revascularization TOTAL ENDOSCOPIC CORONARY ARTERY BYPASS GRAFTING (TECAB)

96

97 Endoscopic Surgery

98 Endoscopic Saphenous Vein Harvesting Complications (wound infection) was reduced significantly by 69% Follow-up angiography of all vein grafts - 6 months after the operation. Cheng D, Allen K, Cohn W, et al: Endoscopic vascular harvest in coronary artery bypass grafting surgery : A meta-analysis analysis of randomized trials and controlled trials. Innovations (in press).

99 Endoscopic -1,753 ; Open 1,247 Angiography months

100

101 Robotics The Da Vinci System Console Visualization Stereo Visualization: Direct connection of surgeon hands to tool tips Registration is both visual and spatial Eye-hand coordination is restored One image per eye

102 Addition of a 3 DOF wrist at the tip (total of 7 DOF)

103

104 Hybrid Procedure

105 Hybrid Revascularization Lima to LAD followed by PCI to other targets- problem if PCI does not succeed PCI to CX and/or RCA territory followed by Minimally invasive LIMA to LAD- problem anti- platelets during surgery and PCI with significant LAD lesion

106 Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up 58 pt s s underwent simultaneous, integrated coronary artery revascularization in an operating theater equipped with angiographic equipment. CONCLUSION: For multivessel coronary artery disease, simultaneous integrated coronary artery revascularization with bivalirudin is safe and feasible. J Thorac Cardiovasc Surg Sep;136(3):702-8

107

108